Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy

Lignende værker

• Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
  af: Norwood, Jamison, et al.
  Udgivet: (2017)
• Weight Gain in Persons with HIV Switched from Efavirenz-based to Integrase Strand Transfer Inhibitor-based Regimens
  af: Norwood, Jamison, et al.
  Udgivet: (2017)
• Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy
  af: Shepherd, Bryan E., et al.
  Udgivet: (2010)
• Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
  af: Bourgi, Kassem, et al.
  Udgivet: (2020)
• Circulating Interleukin-6, Soluble CD14, and Other Inflammation Biomarker Levels Differ Between Obese and Nonobese HIV-Infected Adults on Antiretroviral Therapy
  af: Koethe, John R., et al.
  Udgivet: (2013)